Compare · NTR vs NXTS
NTR vs NXTS
Side-by-side comparison of Nutrien Ltd. (NTR) and Nexentis Technologies Inc. (NXTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTR and NXTS operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- NTR is the larger of the two at $31.25B, about 26753.2x NXTS ($1.2M).
- NXTS has been more active in the news (9 items in the past 4 weeks vs 4 for NTR).
- NTR has more recent analyst coverage (25 ratings vs 0 for NXTS).
- Company
- Nutrien Ltd.
- Nexentis Technologies Inc.
- Price
- -
- -
- Market cap
- $31.25B
- $1.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2004
- News (4w)
- 4
- 9
- Recent ratings
- 25
- 0
NTR
Nutrien Ltd.
Nutrien Ltd. provides crop inputs, services, and solutions. The company offers potash, nitrogen, phosphate, and sulfate products; and financial solutions. It also distributes crop nutrients, crop protection products, seeds, and merchandise products through approximately 2,000 retail locations in the United States, Canada, South America, and Australia. The company was incorporated in 2017 and is headquartered in Saskatoon, Canada.
Latest NTR
- SEC Form 6-K filed by Nutrien Ltd.
- SEC Form 6-K filed by Nutrien Ltd.
- Nutrien Declares Quarterly Dividend of US$0.55 per Share
- Nutrien Reports Third Quarter 2026 Results
- Nutrien Announces Release Dates for Third Quarter 2026 Results and Conference Call
- SEC Form 6-K filed by Nutrien Ltd.
- Nutrien Provides Update on Trinidad Nitrogen Operations
- Nutrien to Host Investor Day on November 30
- KeyBanc Capital Markets initiated coverage on Nutrien
- Nutrien downgraded by National Bank Financial with a new price target
Latest NXTS
- Nexentis: MitoCareX Progresses Toward In-Vitro Evaluation Following AI-Powered Computational Screening
- Director Kalifi Udi Ovadia was granted 3,875 units of Restricted Shares of Common Stock (SEC Form 4)
- SEC Form 10-Q filed by Nexentis Technologies Inc.
- Nexentis Technologies Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- SEC Form PRE 14A filed by Nexentis Technologies Inc.
- Nexentis Technologies Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Nexentis Announces Reverse Stock Split
- Nexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with Boltz
- Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage
- SEC Form 4 filed by Nexentis Technologies Inc.